Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.55 |
| ▸ | FFAR4 | Q5NUL3 | 10/20 | 0.41 |
| ▸ | DHFR | P00374 | 2/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18768202 | 0.80 | HTR2A (0.52) | HTR2AFFAR4DHFRPKMNPSR1 | |
| SCHEMBL21634429 | 0.79 | HTR2A (0.38) | HTR2ADHFR | |
| SCHEMBL1005341 | 0.79 | HTR2A (0.51) | HTR2AFFAR4DHFRPKMNPSR1 | |
| SCHEMBL4750485 | 0.79 | HTR2A (0.51) | HTR2AFFAR4PKMNPSR1ALDH1A1 | |
| SCHEMBL17034856 | 0.76 | HTR2A (0.49) | HTR2AFFAR4DHFRPKMNPSR1 | |
| SCHEMBL16483443 | 0.76 | HTR2A (0.52) | HTR2AFFAR4DHFRPKMNPSR1 | |
| SCHEMBL2439246 | 0.76 | HTR2A (0.52) | HTR2AFFAR4DHFRPKMNPSR1 | |
| SCHEMBL11116337 | 0.76 | HTR2A (0.52) | HTR2AFFAR4PKMNPSR1CYP3A4 | |
| SCHEMBL4230090 | 0.75 | HTR2A (0.48) | HTR2AFFAR4PKMNPSR1 | |
| SCHEMBL12035510 | 0.75 | FFAR4 (0.54) | HTR2AFFAR4DHFRPKMNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116265457-B | N-oxa condensed ring amide compound and preparation method and application thereof | 湖南化工研究院有限公司 | 2024-09-03 | — | — | CN | disclosed |
| CN-116265457-A | N-oxa condensed ring amide compound and preparation method and application thereof | 湖南化工研究院有限公司 | 2023-06-20 | — | — | CN | disclosed |
| US-20110118236-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-05-19 | — | — | US | disclosed |
| EP-2269990-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2011-01-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118236-A1 | HETEROCYCLIC COMPOUND | GRIN1, GRM1, GRIK1 | HTR2A 1059/4885FFAR4 440/4885DHFR 1806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.